L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases (LICC)
LICC: L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases - a Randomized, Placebo-controlled, Multicenter, Multinational, Double Blinded Phase II Trial
Sponsor: Prof. Dr. Carl Schimanski
A PHASE2 clinical study on Colon Carcinoma and Rectum Carcinoma, this trial is completed. The trial is conducted by Prof. Dr. Carl Schimanski and has accumulated 8 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2018 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Prof. Dr. Carl Schimanski
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altenburg, Germany , Berlin, Germany , Darmstadt, Germany , Essen, Germany , Esslingen am Neckar, Germany , Frankfurt, Germany , Hamburg, Germany , Karlsruhe, Germany , Leipzig, Germany , Magdeburg, Germany and 11 more locations